CytoDyn Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Loss Per Common Share (Tables)

Loss Per Common Share (Tables)

9 Months Ended

Feb. 28, 2023

Loss Per Common Share

Schedule of reconciliation of the numerators and denominators of basic and diluted net loss per share


		Three months ended February 28,						Nine months ended February 28,
(in thousands, except per share amounts)		2023			2022			2023			2022
						(Restated) ⁽¹⁾						(Restated) ⁽¹⁾
Net loss		$	(13,702)		$	(41,285)		$	(61,188)		$	(126,699)
Less: Deemed dividends			(123)			—			(5,417)			—
Less: Accrued preferred stock dividends			(366)			(397)			(1,121)			(1,239)
Net loss applicable to common stockholders		$	(14,191)		$	(41,682)		$	(67,726)		$	(127,938)
Basic and diluted:
Weighted average common shares outstanding			832,215			695,614			810,986			663,373
Loss per share		$	(0.02)		$	(0.06)		$	(0.08)		$	(0.19)

(1) See Note 2, Summary of Significant Accounting Policies—Revision and Restatement of Financial Statements.

Schedule of securities excluded from computation of earnings per share


	Three and nine months ended February 28,
(in thousands)	2023		2022
Stock options, warrants, and unvested restricted stock units	203,274		98,309
Convertible notes	12,000		12,000
Convertible preferred stock	33,323		32,197